Precision for Medicine acquires industry-leading AI technology and builds on the cloud-based Multiomics data integration and Informatics platform QuartzBio(TM) significantly

Bethesda, Maryland (ots/PRNewswire) – Precision for Medicine, a part of the Precision Medicine Group, today announced the Acquisition of SimplicityBio, which expanded the Multiomics data integration and Informatics platform QuartzBio(TM) from Precision to artificial intelligence. The extension of QuartzBio an artificial intelligence Engine provides customers with Precision the most stable and the most demanding of End-to-End solution, with the help of which you can master the Big Data challenge of biomarker-driven drug development. She supports customers in their Mission, the value and Benefit of the in the context of a clinical trial generated a biomarker data to maximize.

THE EXTENSION TO THE NATIVE ARTIFICIAL INTELLIGENCE PROVIDES CUSTOMERS WITH INTUITIVE, INTERPRETABLE AND INTERACTIVE BIOMARKER-BASED MODELS

Biomarkers are increasingly at the forefront of precision medicine and are forecast for the prediction and understanding of clinical results in a variety of treatments and population groups is of Central importance. The distribution of biomarker data, however, represents a major challenge for teams of experts, when it comes to creating data sets with millions of data points from several laboratories for different assay types and to integrate. The QuartzBio platform accelerates the coordination and organization of these complex data streams into actionable and integrated records for all of the „Omics“ and clinical information significantly.

The AI approach of SimplicityBio, which was originally developed at the Swiss University of HEIG-VD and after a short time in the industry, utilizes a unique and independent Multiomics approach to the discovery of novel combinations of biomarkers, using a variety of data streams. As a proprietary technology SimplicityBio AI-based Algorithms in the development of complex Multiomics-signatures have been used extensively and is the subject of published were scientific studies on the use of artificial intelligence for biomarker assessment. You have contributed to SimplicityBio as an industry leader in the emerging field of artificial intelligence to the health care system has been able to establish. SimplicityBio also a founding and current Board member of the Alliance for Artificial Intelligence in Healthcare (AAIH), a global organization for advocacy with the emphasis on the promotion and use of artificial intelligence in healthcare.

Thanks to the combination of QuartzBio and SimplicityBio companies can for the first Time to your complete (e.g., genome, transcriptome, proteome, flow cytometry) Multiomics data in real time to access to make data-driven decisions in the context of studies. With the addition of the simplicity of the BIOS analysis platform for artificial intelligence customer KI can examine-based signatures seamlessly in this integrated clinical Omics data sets and the data output in an intuitive, interpretable, interactive and safe way to queries. This actionable data enables a more comprehensive understanding of the disease mechanisms, the discovery of drug targets, identification of biomarkers, patient stratification, and the repositioning of drugs. All of this ultimately leads to more effective treatments and better outcomes for patients.

Chad Clark, President of Precision for Medicine, explains the importance of artificial intelligence for advanced biomarker Informatics applications: „We are very excited to integrate the AI approach of SimplicityBio in our translational Informatics platform QuartzBio. The Integration of our industry-leading functions for Multiomics data processing and harmonisation with proven analysis tools for artificial intelligence is really unique on the market and allows us to offer our customers from the biopharmaceutical sector is a very competitive solution to offer“.

Matthew Hall, CEO and co-founder of SimplicityBio, adds:
„Approaches to artificial intelligence are only as good as the data that we can apply for it. With a Precision for Medicine, and the Integration of our AI Algorithms in QuartzBio we make a big step forward for our customers and the industry, to the increasing quantity and complexity of the Multiomics data.“

Information about Precision for Medicine

As the first biomarker-based clinical development organization supported by Precision for Medicine, Life-Science companies in the use of biomarkers for a more precise and more effective treatment of patients is essential. Precision applies novel Biomarker approaches in clinical research and uses the latest scientific and technological advances. QuartzBio – the Multiomics-based platform for data integration and computing applications-from Precision for Medicine – allows Life Science companies to discover unknown groups of patients who could benefit from a specific therapy, and provides the basis for a truly personalised medicine. Precision for Medicine is part of the Precision Medicine Group with more than 1,800 employees in 30 locations in the United States, Canada, and Europe. For more information about QuartzBio, see quartz.bio.

Information to SimplicityBio

The platform of SimplicityBio uses its own technology on the basis of Machine Learning to the analysis of biological, clinical and digital data streams to generate Knowledge and insights that can lead to the understanding of disease mechanisms, to the discovery of drug targets, identification of biomarkers for stratification of patients and for repositioning of drugs. For more information, see simplicitybio.com.

Louis Landon, Precision Medicine Group
310-984-7707
louis.landon@precisionformedicine.com
Logo mma.prnewswire.com/media/348789/precisioneffect_Logo.jpg